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Why is there an urgent need for development of therapeutic alternatives for chronic hepatitis B ?
Despite of existence of an effective vaccine, chronic hepatitis B virus (HBV) infection is still a global public health problem with at least 370 million virus carriers, who are of a high risk of cirrhosis and hepatocellular carcinoma development. The efficacy of current anti-HBV therapies relaying on IFN- and nucleoside analogues (lamivudine, adefovir) is limited by the emergence of drug-resistant mutants and the persistence of intranuclear covalently closed circular viral DNA (cccDNA) form, responsible for viral relapse after treatment withdrawal (1) . Therefore, this cccDNA pool, which can be considered as a viral minichromosome, plays a crucial role in the persistence of HBV infection and its elimination remains a major clinical challenge.
In this regard, increasing number of evidence from different animal models such as HBVreplicating transgenic mice, HBV-infected chimpanzee, woodchuck HBV (WHV)-infected woodchucks and duck HBV (DHBV)-infected ducks indicate that at least partial viral RNA and cccDNA clearance can be achieved by two not mutually exclusive mechanisms: i/ cytolytic death of infected cells ii/ non cytolytic mechanisms depending of CD8+T cell response via production of TH-1 cytokines such as gamma interferon (IFN- in the liver. It is now evident that chronic hepatitis B is characterized by a weak and narrow HBV-specific T cell response, whereas resolution of infection requires vigorous immune responses, especially polyclonal cytotoxic T-cell (CTL) and T helper 1 (Th1) cell response directed towards different viral epitopes (2) . Therefore, immunotherapeutic approaches aimed at restoring or reactivating HBV-specific immune responses are considered of particular value for chronic hepatitis B therapy (2).
Why is DNA vaccination pertinent for immunotherapy of HBV-carriers ?
DNA vaccination (or genetic vaccination) is an exciting novel immunization approach which was introduced a more than decade ago and became an extremely fast growing field in vaccine In the duck model, DNA vaccines targeting DHBV small (7) or large preS/S (8) envelope proteins were able to induce high-titer anti-S or anti-preS antibodies respectively, which were highly protective in vivo and neutralized viral infectivity in vitro in primary duck hepatocytes (PDH). We provided first evidence that maternal anti-preS antibodies elicited by DNA vaccination were vertically transmitted, protecting progeny of vaccines against high-titer hepadnavirus infection (9).
Our recent data strongly suggest that neutralization capacity of anti-preS antibodies induced by Treatment of DHBV-carriers with entecavir (ETV) and DHBV DNA vaccine showed a potent antiviral effect of drug, however DNA vaccine mono-or combination therapy have not resulted in reduction of viral replication (10) . We showed an additive effect of adefovir and DNA immunization in term of more pronounced decrease in serum and liver viral DNA (11), whereas such synergy was not observed for lamivudine-DNA vaccine combination, probably due to the low antiviral pressure of lamivudine in this model (12) . Interestingly, in a lamivudine-DNA study a potent effect of DNA immunization was observed, since 30% of animals on DNA vaccination combined or not with lamivudine showed viral cccDNA clearance, which was tightly associated with restoration of anti-preS responses (12) .
Because these three studies differed not only by the choice of an antiviral drug but, importantly, by the design of DNA immunization protocol, in our view, number of factors such as: i/ plasmid construct ii/ larger amount of plasmid DNA ii/ higher number of DNA injections and ii/ longer DNA immunization schedule, may play a key role in the potent antiviral efficacy observed in lamivudine-DNA study. The role of T cell response in viral clearance was not examined in these studies since the tools for duck cellular response analysis are still lacking and urgently need to be developed. In this regard, WHV-carrier woodchuck represents a pertinent model to study the impact of therapeutic DNA vaccine on cellular immune response restoration. Surprisingly, in spite of numerous studies in naïve animals, to date, there is no published reports evaluating genetic vaccines, combined or not with antiviral drugs, for chronic WHV-infection, probably because it is much more difficult to break the immune tolerance status in the woodchuck as compared to the duck infection model. It is of interest that following HBV DNA vaccine electroporation to naïve mice and rabbits, an enhancement of both humoral and cellular responses to HBsAg and HBcAg has been recently reported (15) . In addition, a single HBsAg DNA immunization of sheep using EP elicited longterm antibody response of a magnitude considered to be protective, indicating its efficacy in larger species (16) . In my view, DNA electroporation can be a valuable approach for therapeutic HBV DNA vaccine development, which needs to be evaluated and optimized in animal models of chronic hepatitis B in order to obtain a complete and sustain recovery from viral infection for clinical development in a near future.
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